Drug Trial Radar · NCT04187898
Open-Label, Phase 1 Study to Evaluate Duration of Severe Neutropenia After Same-Day Dosing of Eflapegrastim in Patients With Breast-Cancer
Last checked: Nov 20, 2026Latest source record: Sep 19, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
59
Actual
Start
Mar 11, 2020
Primary completion
Jul 16, 2024
Study completion Aug 16, 2024
Sponsor
- Lead sponsor
- Spectrum Pharmaceuticals, IncIndustry
- Sponsor type
- Industry
- First posted
- Dec 5, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to compare the effect of Eflapegrastim on duration of neutropenia in patients with early-stage breast cancer when administered at varying intervals following Docetaxel and Cyclophosphamide administration.
Conditions
- Neutropenia
- Breast Cancer
Interventions
EflapegrastimBiological
Administered in Cycle 1, 30 minutes after TC chemotherapy. Administered in Cycles 2-4, on day 2 of each cycle.
EflapegrastimBiological
Administered in Cycle 1, 3 hours after TC chemotherapy. Administered in Cycles 2-4, on day 2 of each cycle.
EflapegrastimBiological
Administered in Cycle 1, 5 hours after TC chemotherapy. Administered in Cycles 2-4, on day 2 of each cycle.
EflapegrastimBiological
Administered in Cycles 1-4, 30 mins after TC chemotherapy.
DocetaxelDrug
75 mg/m\^2 IV infusion. Administered on Day 1 of each cycle.
CyclophosphamideDrug
600 mg/m\^2 IV infusion. Administered on Day 1 of each cycle.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to Recovery of Absolute Neutrophil Count (ANC) From Nadir to ≥1.5×10^9/L in Cycle 1Time frame: Cycle 1 is 21 days
Locations
8 sites in 1 country. Site status is shown where the registry gives one.
ACRC/ Arizona Clinical Research Center
Tucson, Arizona
Yuma Regional Medical Center Cancer Center
Yuma, Arizona
Pacific Cancer Medical Center
Anaheim, California
City of Hope
Long Beach, California
BRCR Medical Center, Inc.
Plantation, Florida
Bond & Steele Clinic, P.A.
Winter Haven, Florida
SCL Health Research Institute, Inc.
Billings, Montana
Mercy Health Youngstown
Youngstown, Ohio
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.